论文部分内容阅读
探讨卵巢上皮癌组织中Bcl- 2与突变型P53蛋白表达的临床意义及与耐药的关系。方法 :采用免疫组化方法测定 31例初治、19例复发卵巢癌组织中Bcl- 2与P53的表达率。结果 :卵巢癌组织中Bcl - 2阳性表达率为 54% ,P53阳性表达率为 60 %。Bcl - 2表达与临床分期、组织学分级无关。P53在Ⅲ -Ⅳ晚期卵巢癌表达增加。Bcl- 2在初治及复发性卵巢癌者表达无差异 ,复发性卵巢癌组织中P53表达增加。Bcl- 2阳性表达者 2年存活率无明显降低 ,P53高表达者预后不良。结论 :Bcl - 2与P53可能通过调控肿瘤细胞凋亡参与卵巢癌的发生发展 ,Bcl - 2可能在肿瘤发生的早期阶段起作用 ,P53则为后发现象。Bcl - 2与P53之间可能有功能性关联。
To investigate the clinical significance of Bcl-2 and mutant P53 protein expression in ovarian epithelial cancer and its relationship with drug resistance. Methods : The expression of Bcl-2 and P53 in 31 cases of newly diagnosed and 19 cases of recurrent ovarian cancer were detected by immunohistochemistry. Results: The positive rate of Bcl-2 in ovarian cancer was 54%, and the positive rate of P53 was 60%. The expression of Bcl-2 was not associated with clinical stage and histological grade. P53 expression increased in advanced III-IV ovarian cancer. There was no difference in the expression of Bcl-2 in newly diagnosed and recurrent ovarian cancer, and the expression of P53 in recurrent ovarian cancer tissues increased. The 2-year survival rate of patients with positive Bcl-2 expression was not significantly reduced, and patients with high P53 expression had a poor prognosis. Conclusion : Bcl-2 and P53 may be involved in the development of ovarian cancer by regulating the apoptosis of tumor cells. Bcl-2 may play an important role in the early stage of tumorigenesis, and P53 may be later discovered. There may be a functional relationship between Bcl-2 and P53.